Investors are keenly observing key catalysts that may propel specific stocks to outperform the broader market. While predicting the exact trajectory of the stock market in 2026 remains uncertain, analysts are confident that certain companies will thrive based on their upcoming developments.
Alphabet, the parent company of Google, has shown strong performance over the last year despite a recent decline. The company’s position in the artificial intelligence (AI) sector is expected to drive further growth in 2026. Notably, CEO Anat Ashkenazi revealed that Google Cloud’s backlog surged by 55% quarter-over-quarter in Q4, reaching a substantial $240 billion, more than double its year-over-year figure. As Alphabet converts this backlog into recognized revenue, the company’s earnings are set to rise significantly. Furthermore, Alphabet’s innovations, particularly in AI—such as the recent launch of Google Antigravity, which enhances complex software functions using AI agents—suggest exciting growth prospects for 2026.
In the biotech sector, BeOne Medicines, formerly known as BeiGene, is anticipated to generate substantial momentum. The company’s existing blockbuster drug, Brukinsa, leads the market as a top BTK inhibitor, outpacing competitors like Imbruvica. Analysts expect updates from a Phase 3 study that will evaluate Brukinsa combined with rituximab for treating mantle cell lymphoma (MCL) in the first half of 2026. Additionally, BeOne is pursuing U.S. regulatory approval for a new drug, sonrotoclax, aimed at patients with relapsed or refractory MCL. There is also a potential filing for accelerated approval of BGB-16673 for chronic lymphocytic leukemia later in the year, depending on encouraging Phase 2 trial results.
Another promising contender is Rhythm Pharmaceuticals, a mid-cap biotech focused on rare genetic obesity disorders. The company’s sole product, Imcivree, is already approved for three specific indications, but it’s awaiting a crucial FDA decision on a fourth indication for acquired hypothalamic obesity (HO), expected by March 20, 2026. If approved, this could significantly expand Rhythm’s market share. Additionally, the company plans to announce results from a Phase 3 study on Imcivree’s effectiveness in treating various genetic diseases, along with key outcomes from a Phase 2 study on Prader-Willi syndrome, a rare condition that could open further market opportunities.
As these companies position themselves for significant developments in 2026, investors are advised to closely monitor these stocks. The favorable catalysts associated with Alphabet, BeOne Medicines, and Rhythm Pharmaceuticals could make them key players in the market this year.
